Effects of Simvastatin Alone or Combined With Ramipril on Nitric Oxide Bioactivity and Inflammation Markers in Hypercholesterolemic Patients
Korean Circulation Journal
;
: 1053-1059, 2003.
Artigo
em Coreano
| WPRIM
| ID: wpr-54865
ABSTRACT
BACKGROUND AND OBJECTIVES:
Because the mechanisms of the biological effects of statin and antiotensin converting enzyme inhibitor therapies differ, the vascular responses to these therapies were studied in hypercholesterolemic patients. MATERIALS ANDMETHODS:
Simvastatin, 20 mg, placebo or ramipril, 10 mg, were administered daily for 2 months, with a 2 month washout, to 32 hypercholesterolemic patients. This was a randomized, double-blind, placebo-controlled, crossover in design study.RESULTS:
Simvastatin alone, or in combination with ramipril, significantly changed the lipoproteins, and improved the percentage of the flow-mediated dilator response to hyperemia by 46+/-48% and by 59+/-66%, respectively, relative to the baseline measurements (both p<0.001). The plasma malondialdehyde levels were reduced, relative to baseline measurements, by 6+/-57% (p=0.045) and 13+/-47% (p=0.045 and p<0.001, respectively) and plasma levels of monocyte chemoattractant protein-1 by 3+/-27% and by 9+/-16%, respectively (p=0.113 and p=0.001, respectively). The C-reactive protein were also reduced, relative to baseline measurements, by 17+/-75% and by 17+/-37%, respectively (p=0.003 and p=0.001, respectively). However, simvastatin combined with ramipril changed, to a greater extent, but was statistically insignificant, the percentage of the flow-mediated dilator response to hyperemia, and the plasma monocyte chemoattractant protein-1 levels, than simvastatin alone.CONCLUSION:
Compared with simvastatin alone, the addition of ramipril improved the endothelial function to greater extent, but was statistically insignificant, in hypercholes-terolemic patients.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Plasma
/
Proteína C-Reativa
/
Ramipril
/
Quimiocina CCL2
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Sinvastatina
/
Hiperemia
/
Inflamação
/
Lipoproteínas
/
Malondialdeído
Tipo de estudo:
Ensaio Clínico Controlado
Limite:
Humanos
Idioma:
Coreano
Revista:
Korean Circulation Journal
Ano de publicação:
2003
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS